In ₹ Crore except Per Share Latest Annual	GRANULES FY26	AUROPHARMA FY26	IPCALAB FY26	AARTIDRUGS FY26	Peer Average
Valuation — at last close
P/E	34.35×	27.26×	42.92×	◆ 20.97×	30.38× +13%
P/B	4.10×	◆ 2.52×	6.07×	2.64×	3.74× +9%
EV/EBITDA	17.90×	◆ 13.52×	25.24×	15.05×	17.94× 0%
Market Cap	₹20,826 Cr	₹95,530 Cr	₹48,977 Cr	₹4,088 Cr	₹49,532 Cr -58%
Growth
Revenue CAGR 3Y	5.95%	10.63%	◆ 15.60%	-1.89%	8.11% -27%
Revenue CAGR 5Y	10.63%	6.32%	◆ 12.22%	3.55%	7.36% +44%
Net Income CAGR 3Y	4.82%	22.03%	◆ 35.20%	5.43%	20.89% -77%
Revenue YoY (latest Q)	◆ 22.04%	16.30%	20.76%	19.01%	18.69% +18%
Net Income YoY (latest Q)	59.77%	25.22%	◆ 82.18%	-7.12%	33.43% +79%
Profitability
EBITDA Margin	◆ 22.09%	20.34%	20.51%	12.05%	17.63% +25%
Net Income Margin	11.09%	10.41%	◆ 12.27%	7.60%	10.09% +10%
Return on Common Equity	13.52%	9.94%	◆ 15.20%	13.36%	12.83% +5%
Return on Capital Employed	◆ 18.00%	13.41%	16.05%	13.34%	14.27% +26%
Return on Assets	8.52%	6.47%	◆ 9.81%	7.23%	7.84% +9%
Credit & Quality
Total Debt/Equity	0.26×	0.20×	◆ 0.07×	0.37×	0.21× +22%
Interest Coverage	7.77×	13.20×	◆ 20.55×	7.19×	13.65× -43%
Scale — latest FY
Revenue / Total Income	₹5,366 Cr	₹33,653 Cr	₹9,646 Cr	₹2,565 Cr	₹15,288 Cr -65%
Net Income	₹595 Cr	₹3,503 Cr	₹1,184 Cr	₹195 Cr	₹1,627 Cr -63%
Total Assets	₹7,720 Cr	₹58,502 Cr	₹12,370 Cr	₹2,815 Cr	₹24,563 Cr -69%
EPS	₹24.47	₹60.34	₹44.98	₹21.36	₹42.23 -42%
Book Value per Share	₹205.21	₹652.39	₹317.85	₹169.7	₹379.98 -46%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.